FibroGen (FGEN)
(Delayed Data from NSDQ)
$0.37 USD
-0.04 (-8.93%)
Updated Sep 23, 2024 03:59 PM ET
After-Market: $0.37 0.00 (-0.56%) 5:50 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
FGEN 0.37 -0.04(-8.93%)
Will FGEN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for FGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FGEN
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
Pfizer (PFE) Tops Q2 Earnings and Revenue Estimates
FGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zoetis (ZTS) Beats Q1 Earnings and Revenue Estimates
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
Here's Why You Should Add Immunovant (IMVT) to Your Portfolio
Other News for FGEN
FibroGen CFO, Chief Medical Officer to leave
FibroGen CFO, CMO to leave company by year's end
FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript
FibroGen Inc.: Sell Rating Maintained Amid Uncertainties and Limited Upside Potential